A recent statement by FDA senior official Janet Woodcock suggests that while the FDA is reluctant to litigate over the scope of First Amendment commercial speech and will limit its challenges to industry promotional practices going forward, companies can police themselves as in the United Kingdom.
Not With A Bang, But A Whimper . . . FDA Capitulates On Off-Label Regulation
